Literature DB >> 6889920

Etoposide as single agent and in combination with cis-platinum for malignant lymphomas.

T Kroner, J P Obrecht, W F Jungi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6889920     DOI： 10.1016/s0305-7372(82)80076-5

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  5 in total

1.  Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin.

Authors:  P Comella; G Abate; G Di Finizio; A Daponte; D Zarrilli
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  Cisplatin, VP-16-213 and MGBG (methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study.

Authors:  L Dabich; M K Liepman
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

Review 4.  Cisplatin: a review of clinical applications and renal toxicity.

Authors:  D T Sleijfer; S Meijer; N H Mulder
Journal:  Pharm Weekbl Sci       Date:  1985-12-13

5.  EVA treatment for recurrent or unresponsive Hodgkin's disease.

Authors:  M A Richards; J H Waxman; T Man; T S Ganesan; M J Barnett; P F Wrigley; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.